Pheon

Pheon Therapeutics is an expert in antibody-drug conjugates (ADCs), developing a pipeline of single therapies for novel targets and payloads. ADCs have the potential to treat solid tumors and liquid cancers that are unresponsive to other treatments. Pheon’s lead program is a first-in-class ADC targeting a novel target, which has shown promise in solid tumors across multiple refractory cancer types.